MedTrace Logo

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

NCT06298565 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 680

Last updated 2026-02-17

No results posted yet for this study

Summary

This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.

Conditions

Interventions

BIOLOGICAL

efgartigimod

efgartigimod

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-04
Primary Completion
2034-06-30
Completion
2034-06-30
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Belgium
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06298565 on ClinicalTrials.gov